CL2022000086A1 - Vacunas contra ehrlichia y composiciones inmunogénicas - Google Patents
Vacunas contra ehrlichia y composiciones inmunogénicasInfo
- Publication number
- CL2022000086A1 CL2022000086A1 CL2022000086A CL2022000086A CL2022000086A1 CL 2022000086 A1 CL2022000086 A1 CL 2022000086A1 CL 2022000086 A CL2022000086 A CL 2022000086A CL 2022000086 A CL2022000086 A CL 2022000086A CL 2022000086 A1 CL2022000086 A1 CL 2022000086A1
- Authority
- CL
- Chile
- Prior art keywords
- ehrlichia
- immunogenic compositions
- vaccines
- adjuvant
- canis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
En este documento se proporcionan composiciones inmunogénicas que pueden ser utilizadas, en algunos aspectos, para inducir una respuesta inmune contra una Ehrlichia tal como Ehrlichia canis. En algunas modalidades, la composición inmunogénica comprende una bacterina de E. canis y/o adyuvante, tal como por ejemplo una emulsión o adyuvante liposomal. También se proporcionan métodos relacionados, como para el diagnóstico o la vacunación contra la ehrlichiosis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962873843P | 2019-07-12 | 2019-07-12 | |
US201962879762P | 2019-07-29 | 2019-07-29 | |
US202063049476P | 2020-07-08 | 2020-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000086A1 true CL2022000086A1 (es) | 2022-09-30 |
Family
ID=71948757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000086A CL2022000086A1 (es) | 2019-07-12 | 2022-01-12 | Vacunas contra ehrlichia y composiciones inmunogénicas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220356231A1 (es) |
EP (1) | EP3996741A1 (es) |
JP (1) | JP2022540197A (es) |
CN (1) | CN114514238A (es) |
AU (1) | AU2020314625A1 (es) |
BR (1) | BR112022000347A2 (es) |
CA (1) | CA3146842A1 (es) |
CL (1) | CL2022000086A1 (es) |
MX (1) | MX2022000525A (es) |
WO (1) | WO2021011456A1 (es) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043085A (en) * | 1998-08-27 | 2000-03-28 | Research Development Foundation | Ehrlichia canis 120-kDa immunodominant antigenic protein and gene |
DE60316189T2 (de) * | 2002-11-04 | 2007-12-20 | Research Development Foundation, Carson City | P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon |
US20050202046A1 (en) * | 2004-03-11 | 2005-09-15 | Wyeth | Canine vaccine for protection against ehrlichiosis |
ES2715280T3 (es) * | 2005-04-04 | 2019-06-03 | Idexx Lab Inc | DIVA de Erlichia canis (Diferenciación entre Animales Vacunados e Infectados) |
US7842474B2 (en) * | 2005-04-04 | 2010-11-30 | Idexx Laboratories, Inc. | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) |
WO2006138509A2 (en) * | 2005-06-16 | 2006-12-28 | Research Development Foundation | Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis |
JP5610766B2 (ja) * | 2006-06-27 | 2014-10-22 | ウェリントン ラボラトリーズ インコーポレイティッド | グリチルレチン酸誘導体 |
ES2397548T5 (es) * | 2006-08-31 | 2021-05-06 | Res Found Dev | Glicoproteína inmunorreactiva gp19 de Ehrlichia canis |
HUE028921T2 (en) * | 2008-06-27 | 2017-01-30 | Zoetis Services Llc | New adjuvant preparations |
WO2010126993A1 (en) * | 2009-04-28 | 2010-11-04 | Research Development Foundation | Immunoreactive ehrlichia p120/p140 epitopes and uses thereof |
EP2575878B1 (en) * | 2010-05-28 | 2018-06-13 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules |
EP2433646A1 (en) * | 2010-09-22 | 2012-03-28 | Intervet International BV | Vaccine against Ehrlichia canis and associated methods |
AU2013267716B2 (en) * | 2012-05-31 | 2018-03-08 | Zoetis Services Llc | Vaccination with Canine Respiratory Coronavirus for protection against B. bronchiseptica infections |
EP3046580A2 (en) * | 2013-09-19 | 2016-07-27 | Zoetis Services LLC | Oil-based adjuvants |
AU2019311181A1 (en) * | 2018-07-27 | 2021-02-18 | Research Development Foundation | Chimeric immunogenic polypeptides |
-
2020
- 2020-07-13 WO PCT/US2020/041779 patent/WO2021011456A1/en unknown
- 2020-07-13 US US17/626,866 patent/US20220356231A1/en active Pending
- 2020-07-13 JP JP2022501147A patent/JP2022540197A/ja active Pending
- 2020-07-13 CN CN202080064004.XA patent/CN114514238A/zh active Pending
- 2020-07-13 EP EP20751422.5A patent/EP3996741A1/en active Pending
- 2020-07-13 MX MX2022000525A patent/MX2022000525A/es unknown
- 2020-07-13 CA CA3146842A patent/CA3146842A1/en active Pending
- 2020-07-13 AU AU2020314625A patent/AU2020314625A1/en not_active Abandoned
- 2020-07-13 BR BR112022000347A patent/BR112022000347A2/pt unknown
-
2022
- 2022-01-12 CL CL2022000086A patent/CL2022000086A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020314625A1 (en) | 2022-02-03 |
WO2021011456A1 (en) | 2021-01-21 |
US20220356231A1 (en) | 2022-11-10 |
EP3996741A1 (en) | 2022-05-18 |
CA3146842A1 (en) | 2021-01-21 |
JP2022540197A (ja) | 2022-09-14 |
MX2022000525A (es) | 2022-04-20 |
BR112022000347A2 (pt) | 2022-04-12 |
CN114514238A (zh) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
BRPI1013780A2 (pt) | composições para imunização contra staphylococcus aureus. | |
AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
CL2015001111A1 (es) | Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna. | |
AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
CL2022000774A1 (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
CL2016002402A1 (es) | Composiciones inmunológicas que contiene histophilus somni atenuado | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
CO2018003460A2 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
CL2015002741A1 (es) | Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos | |
UY32208A (es) | Uso de antigeno de mycoplasma bovis | |
DOP2018000209A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
BR112018069100A2 (pt) | uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae | |
AR089995A1 (es) | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
PL404247A1 (pl) | Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis | |
BR112018073254A2 (pt) | adjuvante agrícola | |
CL2022000086A1 (es) | Vacunas contra ehrlichia y composiciones inmunogénicas | |
AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene |